[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Lo Muzio L: Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis; 2008;3:32
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevoid basal cell carcinoma syndrome (Gorlin syndrome).
  • Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is a hereditary condition characterized by a wide range of developmental abnormalities and a predisposition to neoplasms.
  • The estimated prevalence varies from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1.
  • Main clinical manifestations include multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, hyperkeratosis of palms and soles, skeletal abnormalities, intracranial ectopic calcifications, and facial dysmorphism (macrocephaly, cleft lip/palate and severe eye anomalies).
  • Recurrent jaw cysts occur in 90% of patients.
  • Clinical diagnosis relies on specific criteria.
  • Gene mutation analysis confirms the diagnosis.
  • Antenatal diagnosis is feasible by means of ultrasound scans and analysis of DNA extracted from fetal cells (obtained by amniocentesis or chorionic villus sampling).
  • Surgery for BBCs is indicated when the number of lesions is limited; other treatments include laser ablation, photodynamic therapy and topical chemotherapy.
  • [MeSH-major] Basal Cell Nevus Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:19-23 [14616807.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1236-40 [14725671.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):934-41 [14871823.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] J Dermatolog Treat. 2004 Apr;15(2):120-1 [15204165.001]
  • [Cites] Clin Exp Dermatol. 2004 Sep;29(5):542-4 [15347344.001]
  • [Cites] Hum Mutat. 2004 Nov;24(5):441 [15459969.001]
  • [Cites] Arch Fr Pediatr. 1968 Nov;25(9):1083-93 [5728392.001]
  • [Cites] Med Hist. 1969 Jul;13(3):294-7 [4893629.001]
  • [Cites] J Neurosurg. 1971 Nov;35(5):577-84 [5000945.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):140-8 [4950929.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1976 Jan;84(1):107-12 [1251730.001]
  • [Cites] J Neurosurg. 1979 Jan;50(1):100-2 [758369.001]
  • [Cites] Cancer. 1979 Dec;44(6):2294-305 [509397.001]
  • [Cites] Br J Oral Surg. 1979 Nov;17(2):135-46 [298837.001]
  • [Cites] Hautarzt. 1981 Sep;32(9):455-8 [7275582.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):815-23 [6950957.001]
  • [Cites] Ann Neurol. 1982 Apr;11(4):372-6 [7103417.001]
  • [Cites] Wien Klin Wochenschr. 1982 Sep 3;94(16):430-4 [7147982.001]
  • [Cites] Med Pediatr Oncol. 1983;11(3):178-9 [6855699.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):231-6 [6703200.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):210-2 [6707662.001]
  • [Cites] Can Med Assoc J. 1985 May 1;132(9):1037-8 [3986729.001]
  • [Cites] N Engl J Med. 1986 Mar 13;314(11):700-6 [3951494.001]
  • [Cites] J Am Acad Dermatol. 1986 Nov;15(5 Pt 1):1023-30 [3537024.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] J Am Acad Dermatol. 1987 May;16(5 Pt 1):964-70 [3584581.001]
  • [Cites] J Comput Assist Tomogr. 1987 Sep-Oct;11(5):901-4 [3655059.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):528-31 [3676586.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):309-14 [9096762.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(5):519-22 [17139991.001]
  • [Cites] Childs Nerv Syst. 2007 Jan;23(1):133-6 [16977487.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):202-3 [16780502.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4 Suppl):315-20 [17328283.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Am J Otolaryngol. 2007 Sep-Oct;28(5):360-2 [17826543.001]
  • [Cites] J Drugs Dermatol. 2007 Sep;6(9):910-4 [17941362.001]
  • [Cites] Hum Genet. 2007 Dec;122(5):459-66 [17703323.001]
  • [Cites] Br J Cancer. 1997;76(2):141-5 [9231911.001]
  • [Cites] Ann Plast Surg. 1997 Oct;39(4):366-73 [9339279.001]
  • [Cites] Am J Med Genet. 1997 Dec 19;73(3):304-7 [9415689.001]
  • [Cites] Curr Opin Pediatr. 1997 Dec;9(6):630-5 [9425597.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Laryngoscope. 1998 Feb;108(2):280-3 [9473082.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):187-91 [9592846.001]
  • [Cites] J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S82-5 [9703130.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):291-7 [9931336.001]
  • [Cites] Clin Genet. 1999 Jan;55(1):34-40 [10066029.001]
  • [Cites] J Am Dent Assoc. 1999 May;130(5):669-74 [10332131.001]
  • [Cites] Dermatologica. 1963;126:106-23 [13954184.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):495-502 [15545745.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Ear Nose Throat J. 2004 Oct;83(10):716-8 [15586876.001]
  • [Cites] Ann Hum Genet. 2004 Nov;68(Pt 6):536-45 [15598212.001]
  • [Cites] Ann Plast Surg. 2004 Dec;53(6):593-5 [15602259.001]
  • [Cites] Arch Dermatol Res. 2005 Jan;296(7):303-8 [15565302.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):665-8 [15684600.001]
  • [Cites] Am J Med Genet A. 2005 Jan 30;132A(3):324-8 [15690381.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322-3 [15712338.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S256-9 [16227103.001]
  • [Cites] Genet Med. 2005 Nov-Dec;7(9):611-9 [16301862.001]
  • [Cites] Prenat Diagn. 2005 Nov;25(11):997-9 [16231297.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Echocardiography. 2006 Jan;23(1):79-80 [16412193.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Ann Dermatol Venereol. 2006 Feb;133(2):117-23 [16508594.001]
  • [Cites] Tex Heart Inst J. 2006;33(1):88-90 [16572881.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):e16 [16582078.001]
  • [Cites] Tumour Biol. 2006;27(4):175-80 [16675912.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):417-26 [16788928.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):877-8 [16898919.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):548-53 [16909134.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] Dermatol Surg. 2002 Mar;28(3):287-90 [11896785.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Am J Med Genet. 2002 Jul 15;110(4):400-3 [12116218.001]
  • [Cites] Mol Genet Metab. 2002 May;76(1):57-61 [12175781.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):233-4 [12204003.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):569-72 [12459530.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):47-50 [12604725.001]
  • [Cites] Clin Nucl Med. 2002 Dec;27(12):913-4 [12607884.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):451-2 [12655573.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):1093-5 [12712116.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S64-6 [12734479.001]
  • [Cites] Pediatr Neurol. 2003 Mar;28(3):231-4 [12770681.001]
  • [Cites] Neuroradiology. 2003 Jun;45(6):390-2 [12756507.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Oct;3(10):575-80 [17019435.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1084-6 [17021131.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S86-9 [17052541.001]
  • [Cites] Am J Med Genet A. 2006 Dec 1;140(23):2625-30 [16906569.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):790-4 [10782799.001]
  • [Cites] Brain Dev. 2000 Jun;22(4):272-4 [10838118.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):140-6 [10868476.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • [Cites] Cutis. 2000 Jul;66(1):35-8 [10916689.001]
  • [Cites] Arch Dermatol Res. 2000 Sep;292(9):475-6 [11000293.001]
  • [Cites] Br Dent J. 2001 Apr 14;190(7):349-50 [11338037.001]
  • [Cites] J Dermatol Sci. 2001 Sep;27(1):21-6 [11457640.001]
  • [Cites] Dermatologica. 1987;175 Suppl 1:138-44 [3480250.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Dec;64(6):727-30 [3480489.001]
  • [Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]
  • [Cites] J Am Dent Assoc. 1988 Jun;116(7):887-9 [3164743.001]
  • [Cites] J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85 [3165982.001]
  • [Cites] Presse Med. 1988 Nov 26;17(42):2247-50 [2974590.001]
  • [Cites] Dentomaxillofac Radiol. 1987;16(2):99-103 [3333752.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Jun;47(6):629-33 [2656943.001]
  • [Cites] J Am Acad Dermatol. 1989 Jul;21(1):144-5 [2745766.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Aug;15(8):868-71 [2754091.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):64-6 [2045256.001]
  • [Cites] Pediatr Radiol. 1991;21(3):234-5 [2047170.001]
  • [Cites] Genet Couns. 1990;1(3-4):273-7 [2098052.001]
  • [Cites] Am J Med Genet. 1991 Aug 1;40(2):206-10 [1910262.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1494-8 [1540957.001]
  • [Cites] Genet Couns. 1991;2(3):157-62 [1801852.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):255-62 [1570241.001]
  • [Cites] Pediatr Pathol. 1992 May-Jun;12(3):441-7 [1409143.001]
  • [Cites] Cesk Pediatr. 1993 Mar;48(3):129-32 [8495514.001]
  • [Cites] Dermatology. 1993;186(4):311-2 [8513207.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):760-7 [8352281.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):447-8 [8012356.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):272-81 [8042672.001]
  • [Cites] Am J Med Genet. 1994 Apr 15;50(3):282-90 [8042673.001]
  • [Cites] Lancet. 1994 Aug 13;344(8920):477 [7914587.001]
  • [Cites] Bol Asoc Med P R. 1993 Jan-Mar;85(1-3):24-6 [8060441.001]
  • [Cites] Prenat Diagn. 1994 Aug;14(8):725-7 [7991513.001]
  • [Cites] Genomics. 1994 Aug;22(3):505-11 [8001963.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):472-80 [7856756.001]
  • [Cites] Pediatr Dermatol. 1994 Dec;11(4):323-6 [7899182.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):361-8 [7795971.001]
  • [Cites] Br J Radiol. 1995 Jun;68(810):596-9 [7627481.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Arch Dermatol. 1996 Jan;132(1):94-5 [8546496.001]
  • [Cites] Neurology. 1996 Feb;46(2):574-6 [8614540.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Br J Ophthalmol. 1996 Apr;80(4):378 [8703894.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):7-8 [8782809.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Histopathology. 1996 Sep;29(3):247-52 [8884353.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):286-8 [9010431.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • (PMID = 19032739.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 164
  • [Other-IDs] NLM/ PMC2607262
  •  go-up   go-down


2. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I: Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer; 2009;9:262
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.
  • BACKGROUND: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery.
  • The aim of this work was to evaluate the effect of a formulation containing IFNs-alpha and -gamma in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).
  • METHODS: Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks.
  • They had been previously treated with surgery and/or radiotherapy or chemotherapy.
  • Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor.
  • At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained.
  • None of the patients relapsed during the treatment period.
  • Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.
  • CONCLUSION: The peri- and intralesional combination of IFNs-alpha and -gamma was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients.
  • This is the first report of such treatment in patients with advance non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Interferons / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bayes Theorem. Drug Resistance, Neoplasm. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Prospective Studies. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2357-60 [10875919.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40 [11271459.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):933-7 [12072058.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jun;22(6):719-28 [12162884.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1485-95 [12368221.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):116-20 [14692941.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):342-6 [2405109.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1105-11 [2108862.001]
  • [Cites] Int Ophthalmol. 1990 Jul;14(4):285-94 [2370130.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(5):321-4 [2115817.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1637-49 [2120392.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] Arch Dermatol. 1990 Dec;126(12):1660 [2256701.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9 [1869642.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ann Ophthalmol. 1993 Jan;25(1):11-3 [8427483.001]
  • [Cites] Drug Saf. 1994 Feb;10(2):115-50 [7516663.001]
  • [Cites] J Am Acad Dermatol. 1994 Nov;31(5 Pt 2):916-20 [7962748.001]
  • [Cites] Drugs. 1995 Jul;50(1):48-61 [7588089.001]
  • [Cites] Chin Med Sci J. 2007 Mar;22(1):38-43 [17441316.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1974-8 [17513803.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):889-92 [17638733.001]
  • [Cites] J Immunother. 2008 Jan;31(1):28-33 [18157009.001]
  • [Cites] Acta Pol Pharm. 2008 May-Jun;65(3):345-51 [18646554.001]
  • [Cites] J Immunother. 2008 Sep;31(7):599-606 [18600184.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):205-13 [18849299.001]
  • [Cites] Br J Nurs. 2009 Mar 26-Apr 8;18(6):346, 348-50 [19329898.001]
  • [Cites] Cancer Detect Prev. 1997;21(2):191-5 [9101080.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2691-6 [9389732.001]
  • [Cites] Dermatol Clin. 1998 Apr;16(2):377-98 [9589211.001]
  • [Cites] Acta Oncol. 1999;38(5):613-7 [10427950.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1849-57 [15547726.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):300-4 [15619125.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2937-46 [15837745.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):217-22 [10605014.001]
  • (PMID = 19643007.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9008-11-1 / Interferons
  • [Other-IDs] NLM/ PMC2724551
  •  go-up   go-down


3. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • BCC is mainly located on sun exposed sites, being head and neck the areas of more incidence; although nose, eyelids and periorbitary tissue are unfavorable due to cosmetic results that BCC involves.
  • Several treatment options as surgical and non-surgical are available.
  • The goal of treatment is complete excision of the tumor with preservation of surrounding structures in a way aesthetically acceptable.
  • Mohs' micrographic surgery is the standard treatment for all non-melanoma skin cancer.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The tissue beneath the surgical site can be left for second-intention granulation or covered with a cutaneous implant of partial thickness.
  • The case of a 77 year-old patient is presented with BCC of inferior eyelid of 14 years duration, formerly managed with radiotherapy and, due to recurrent illness and invasion to the maxillary antrum; he needed supraestructure maxillectomy with left orbital exenteration.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


Advertisement
4. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Two patients had perineural invasion; one received adjuvant radiotherapy postoperatively but the other did not due to receiving systemic chemotherapy for recurrent NHL.
  • Perineural invasion is frequently encountered in this situation and should be treated with adjuvant radiation therapy to decrease the likelihood of local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


5. Salvini C, Massi D, Cappugi P: Recurrent basal cell carcinoma of the nose successfully treated by photodynamic therapy. J Eur Acad Dermatol Venereol; 2009 Jan;23(1):73-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basal cell carcinoma of the nose successfully treated by photodynamic therapy.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Nose / pathology. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462294.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Soler AM, Warloe T, Tausjø J, Giercksky KE: Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid. Acta Oncol; 2000;39(5):605-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid.
  • This study was conducted to assess the efficacy of aminolevulinic acid-based photodynamic treatment for residual or recurrent basal cell carcinomas after radiotherapy.
  • Photodynamic therapy with either topical 5-aminolevulinic acid 20% and dimethylsulfoxide 99% pretreatment or topical methylester aminolevulinic acid 20% w/w in cream and subsequent light illumination of 50-200 J/cm2 was performed after an initial skin shaving procedure in 20 patients with 22 residual or recurrent basal cell carcinomas.
  • Three lesions were treated once, while twelve, three, one and two lesions received two, three, four and five treatment sessions respectively.
  • At examination, 6-40 months (mean 22 months) after the last treatment, 18 lesions were in complete remission.
  • Three lesions responded only partially to photodynamic therapy and a fourth lesion recurred 21 months after photodynamic treatment.
  • Two of these four lesions were confirmed as the morpheaform type of basal cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11093368.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] NORWAY
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


7. RUIZ-VILLAVERDE R, SANCHEZ-CANO D, BURKHARDT-PEREZ P, SINTES RN: Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma? Eur J Dermatol; 2009 Sep-Oct;19(5):481-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma?
  • Basal cell carcinoma (BCC) is a cutaneous malignancy with a tendency to spread locally and with several clinical and histological subsets.
  • We studied 34 patients with a clinical diagnosis of recurrent BCC on different anatomical locations, to whom imiquimod 5% cream was administered on a low-frequency regime (3 times a week for 6 weeks), with a minimum of 3 years follow-up after completion of treatment.
  • We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527989.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


8. Yang QS, Gu JL, Du LQ, Jia LL, Qin LL, Wang Y, Fan FY: ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines. J Radiat Res; 2008 Jul;49(4):399-407
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ShRNA-mediated Ku80 gene silencing inhibits cell proliferation and sensitizes to gamma-radiation and mitomycin C-induced apoptosis in esophageal squamous cell carcinoma lines.
  • To investigate the effects of Ku80 depletion on cell growth and sensitization to gamma-radiation and MMC-induced apoptosis in esophageal squamous cell carcinoma lines.
  • Six human carcinoma cell lines (LNcaP, K562, MDA-MB-231, MCF-7, EC9706, and K150) and normal HEK293 cell line were examined for basal levels of Ku80 protein by western blotting analysis.
  • Cell proliferation was determined with MTT assay and colony formation assay and tumorigenicity in a xenograft model in vitro and in vivo.
  • The cell cycle distribution was determined by Flow cytometry.
  • Ku80 showed higher basal levels in six carcinoma cell lines than in HEK293.
  • Ku80 plays an important role not only in tumorigenesis but also in radiation resistance and chemotherapy resistance in esophageal cancer cells.
  • Hence Ku80 may serve as a promising therapeutic target, particularly for recurrent esophageal tumors.
  • [MeSH-major] Antigens, Nuclear / metabolism. Apoptosis / drug effects. Apoptosis / radiation effects. Carcinoma, Squamous Cell / metabolism. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. DNA-Binding Proteins / metabolism. Esophageal Neoplasms / metabolism. Mitomycin / administration & dosage
  • [MeSH-minor] Cell Line, Tumor. Gamma Rays. Gene Silencing. Humans. RNA, Small Interfering / genetics. Radiation Tolerance / drug effects. Radiation Tolerance / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403903.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; 0 / RNA, Small Interfering; 50SG953SK6 / Mitomycin
  •  go-up   go-down


9. Gayl Schweitzer V: Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope; 2001 Jun;111(6):1091-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients.
  • OBJECTIVES/HYPOTHESIS: Aggressive nonmelanomatous skin tumors (basal cell carcinoma, squamous cell carcinoma, and Bowen's disease) of the head and neck often occur in Caucasian elderly patients because of prior history of radiation therapy for teenage acne and adenoid hypertrophy; severe solar-induced skin damage, basal cell nevus syndrome, and other genetic skin diseases; chemical carcinogen exposure; and drug-induced immunosuppression.
  • In patients with large, multifocal recurrent tumors, standard therapy with acceptable cosmetic outcomes may be difficult.
  • Photodynamic therapy (PDT) with photosensitizing agents selectively taken up by skin provides a primary or adjunct intraoperative option for treatment of this special group of cancer patients.
  • RESULTS: Twelve cases of aggressive recurrent nonmelanomatous cutaneous tumors of the head and neck were treated.
  • Seven patients were treated with PDT alone for extensive multiple cutaneous lesions or wide-field primary or recurrent nonmelanomatous tumors.
  • CONCLUSIONS: PHOTOFRIN-mediated PDT is an excellent locoregional oncological modality for aggressive primary or recurrent basal cell carcinoma and squamous cell carcinoma, particularly in elderly patients who were previously treated with extensive Mohs microsurgery, surgical resection, and external-beam radiation therapy.
  • Multiple repeat treatments are well tolerated, painless, without systemic morbidity, and amenable to local anesthesia or intravenous sedation for PDT alone, and wound healing and cosmetic outcomes are excellent.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hematoporphyrin Photoradiation. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Dihematoporphyrin Ether. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404627.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


10. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • The aim of the present study was to evaluate the efficacy of photodynamic therapy on recurrent BCC and SCC lesions on head and neck skin.
  • PATIENTS AND METHODS: A total of 30 patients, including 16 men and 14 women, were selected from patients with recurrent SCC and BCC who referred to Iran university ENT research center Rasool-e-Akram Hospital, Tehran-Iran, met the criteria and entered the study.
  • This is a longitudinal study of 30 patients with 43 histologically verified head and neck skin tumors, candidate for photodynamic therapy.
  • RESULTS: To cite the results obtained in this study, it is worth mention that five cases expressed disagreement with this treatment modality after the first session of illumination; the treatment was stopped because of pain or burning.
  • In a three-month evaluation, complete treatment response rates were obtained in 72% of patients (18 cases); in SCC cases it was 71.4% (10 cases) and in BCC it was 72.7% (eight cases).
  • The final result of complete response rate in three years of follow up, demonstrated that 16 (64%) patients out of 25 were disease-free from recurrent BCC and SCC (Table 1).
  • Hence, there was no statistical difference between SCC and BCC cases to treatment (P = 0.34).
  • DISCUSSION: The obtained data from the current study is supportive of the recommended treatment method of PDT as an effective, tolerable and less invasive treatment in patients with recurrent BCC and SCC carcinomas, particularly when cosmetic effects are an important consideration.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


11. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G: Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol; 2009 Aug;36(8):878-81
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
  • An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder.
  • The patient was treated with curettage followed by the application of topical imiquimod 5% cream five times a week.
  • Depigmentation was noted in the treated area 11 months after the initiation of treatment with imiquimod.
  • The depigmented area did not resolve 14 months after treatment initiation.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Vitiligo / chemically induced. Vitiligo / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Melanocytes / pathology. Skin / pathology. Time Factors

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586497.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


12. Soysal HG, Soysal E, Markoç F, Ardiç F: Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):201-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids and periorbital region in a Turkish population.
  • PURPOSE: To review the clinical and histopathologic features, treatment, and outcomes of eyelid basal cell carcinomas.
  • METHODS: The clinical records and histopathologic specimens of 311 patients with eyelid basal cell carcinomas were reviewed and analyzed retrospectively.
  • The main outcome measures are patient demographics, clinical characteristics, lesion size, duration of lesion, histologic subtypes, presence of orbital and perineural invasion, severity of peritumorous inflammation, treatment modalities, recurrence rate, tumor-related death, and prognostic features.
  • RESULTS: Two-hundred ninety patients underwent surgery whereas others received radiotherapy or chemotherapy.
  • The most common histologic subtypes were infiltrative, nodular, and basosquamous basal cell carcinomas.
  • Nearly one-third (29.9%) of the patients were previously recurrent.
  • Recurrent basal cell carcinomas were larger, with longer duration of lesion and a higher rate of orbital and perineural invasion.
  • Basosquamous basal cell carcinomas were more likely to have prior recurrences, larger lesion size, and the highest rate of orbital invasion.
  • CONCLUSIONS: In this large case series from a single center, the outcomes were worse than previously reported due to delay in treatment and previous inadequate treatments.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520835.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Wu JK, Siller G, Whitehead K: Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol; 2003 May;44(2):123-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream.
  • We report the successful use of topical imiquimod 5% cream for extensive multifocal, recurrent (post cryotherapy), biopsy-proven Bowen's disease of the nose.
  • Treatment was applied on a once-a-day regimen, and a total of 32 applications over 9 weeks were used.
  • A florid local skin reaction occurred early in the treatment, necessitating a rest period and decreasing the frequency of application.
  • The Bowen's disease was coexistent with a multifocal superficial basal cell carcinoma (BCC) that had a partial response.
  • Persistent BCC at 4 weeks post treatment was surgically excised.
  • [MeSH-major] Aminoquinolines / administration & dosage. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12752186.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


14. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 24 patients enrolled: 13 M, 11F; median age 62 (32-77); median number of prior cytotoxic chemotherapy regimens 1 (0-3; 75% with prior RT).
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Huber A, Huber JD, Skinner RB Jr, Kuwahara RT, Haque R, Amonette RA: Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg; 2004 Mar;30(3):429-30
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
  • BACKGROUND: Imiquimod has been used for basal cell carcinomas (BCCs).
  • This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.
  • RESULTS: After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery.
  • All 15 treatment subjects were clear of BCC.
  • At the 18-month follow-up, no patients had recurrent tumor.
  • CONCLUSION: Imiquimod 5% cream may be another treatment modality for nodular BCC.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15008876.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


16. Drehs MM, Cook-Bolden F, Tanzi EL, Weinberg JM: Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg; 2002 May;28(5):427-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
  • BACKGROUND: The use of imiquimod 5% cream for the treatment of superficial basal cell carcinoma (BCC) has been described.
  • OBJECTIVE: To evaluate the efficacy of topical imiquimod in a patient with multiple superficial BCCs unresponsive to topical 5-fluorouracil and to review the literature on this treatment modality for BCCs.
  • The patient was evaluated three months after discontinuation of treatment.
  • There was no clinical evidence of any recurrent tumor.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12030878.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 9
  •  go-up   go-down


17. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC: Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis; 2010 Jun;85(6):318-24
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
  • We conducted a prospective, multicenter, phase 3, open-label study to assess long-term sustained clearance of superficial basal cell carcinomas (sBCCs) treated with imiquimod cream 5%.
  • A biopsy-confirmed tumor (area > or = 0.5 cm2 and diameter < or = 2.0 cm) was treated once daily 7 times per week for 6 weeks.
  • Estimated sustained clearance (proportion of participants who achieved initial clearance at the 12-week posttreatment visit and remained clinically clear at each time point during the long-term follow-up period; N=157) was 85.4% at 60 months (life-table method: 95% confidence interval [CI], 79.3%-91.6%).
  • The overall estimate of treatment success was 80.4% at 60 months (N=169; 95% CI, 74.4%-86.4%).
  • Of 20 recurrent tumors, 74 (70%) occurred within the first 24 months of follow-up.
  • Local skin reactions and application site reactions, the AEs reported by the most participants, occurred predominantly during the treatment period and resolved posttreatment.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666194.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


18. Raspagliesi F, Fontanelli R, Rossi G, Ditto A, Solima E, Hanozet F, Kusamura S: Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study. Gynecol Oncol; 2006 Nov;103(2):581-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget's disease of the vulva: a pilot study.
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (5 ALA) is an effective treatment for some conditions such as Bowen's disease, subsets of basal cell carcinomas and vulvar carcinoma.
  • This paper outlines a pilot study designed to test the feasibility of using MAL-PDT in the treatment of recurrent vulvar Paget's disease.
  • Patients taking part in the study were treated once every 3 weeks, for a total of three treatments.
  • Vulvar biopsies were obtained before and 1 month after the PDT-treatment.
  • The cosmetic outcome was acceptable and the treatment was well tolerated.
  • All the patients developed local edema and mild local pain, controlled with non-steroidal antiinflammatory drugs (NSAIDS).
  • CONCLUSIONS: MAL-PDT is a feasible treatment and seems to offer a reliable strategy in the control of vulvar Paget's disease and of its symptoms.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Paget Disease, Extramammary / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / delta-aminolevulinic acid methyl ester; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


19. Lebwohl M, Tannis C, Carrasco D: Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat; 2003;14 Suppl 2:3-6
Hazardous Substances Data Bank. ACITRETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acitretin suppression of squamous cell carcinoma: case report and literature review.
  • Retinoids have been used for the treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, and in patients with recurrent skin cancers as a result of immunosuppression for renal transplantation.
  • We report a 40-year-old male who began to develop multiple squamous cell carcinomas of the skin after treatment with PUVA for severe psoriasis.
  • The numbers of squamous cell carcinomas increased when acitretin was discontinued and decreased when he was taking the drug at a dose of 25 mg daily.
  • Acitretin should be considered as a maintenance therapy for psoriasis patients developing squamous cell carcinomas as a result of PUVA therapy.
  • [MeSH-major] Acitretin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Keratolytic Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Male. PUVA Therapy / adverse effects. PUVA Therapy / methods. Psoriasis / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14578092.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratolytic Agents; LCH760E9T7 / Acitretin
  • [Number-of-references] 22
  •  go-up   go-down


20. Nashan D, Luger TA: [Cytokines: current status and prospects in the treatment of skin tumors]. Hautarzt; 2001 Aug;52(8):691-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytokines: current status and prospects in the treatment of skin tumors].
  • Various therapeutic options using cytokines have been described in the treatment of melanoma, T cell lymphoma, B cell lymphoma, squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma.
  • The treatment regimens include cytokine substitution, cytokine induction, cytokine transfection and therapeutic cytokine constructs.
  • In the adjuvant treatment of melanomas, IFN-alpha has become well established.
  • IL-2 has a role in the therapy of advanced melanomas as well as in vaccination strategies.
  • Further possible therapeutic immune modulations, which have been evaluated in experimental approaches and pilot studies, include treatment with IL-4, IL-7 and GM-CSF.
  • Treatment with IL-12 promises to open new perspectives.
  • A well established regimen in the treatment of T cell lymphoma stages Ia-IIb is the combination of PUVA and IFN-alpha.
  • IL-2, IFN-gamma, and the fused cytokine-toxin molecules DAB389IL-2 offer further therapeutic alternatives.
  • B cell lymphomas are treated with antibody-IL-2 fusion proteins.
  • Advanced or inoperable squamous cell carcinoma and basal cell carcinoma may be treated with local IFN-alpha injections.
  • IFN-alpha or TNF-alpha may be considered for the treatment of recurrent or advanced Merkel cell carcinoma.
  • In dermatological oncology cytokine treatment focuses on melanome an T cell lymphome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cytokines / therapeutic use. Lymphoma / drug therapy. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Interferon-alpha / therapeutic use. Interleukins / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Melanoma, Experimental / drug therapy. Mice. Neoplasm Recurrence, Local / drug therapy. PUVA Therapy. Palliative Care. Tumor Necrosis Factor-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11544938.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Interferon-alpha; 0 / Interleukins; 0 / Tumor Necrosis Factor-alpha; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 96
  •  go-up   go-down


21. Huang R, Jaffer S: Imprint cytology of metastatic sialoblastoma. A case report. Acta Cytol; 2003 Nov-Dec;47(6):1123-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sialoblastoma is a rare, aggressive and potentially malignant perinatal/congenital tumor that recapitulates the developing salivary gland.
  • CASE: A 75-month-old girl with a history of recurrent sialoblastoma initially diagnosed at 21 months and treated with multiple incomplete surgical excisions, chemotherapy and radiation presented with a solitary lung nodule.
  • The differential diagnoses include neoplasms composed of either basaloid cells and/or admixed hyaline matrix material and included pleomorphic adenoma, basal cell adenoma and adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Glandular and Epithelial / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Disease Progression. Epithelial Cells / pathology. Female. Humans. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Parotid Gland / pathology. Parotid Gland / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674095.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D: Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol; 2010 Jan;162(1):171-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.
  • Background Patients with a previous medical history of nonmelanoma skin cancers (NMSCs) often develop multiple or recurrent malignant lesions around the site of the primary tumour.
  • This finding led to the field cancerization theory, which suggests that the entire epithelial surface of the regional skin has an increased risk for the development of malignant lesions.
  • Objectives We sought to investigate whether field-photodynamic therapy (PDT) of extreme photodamaged skin would prevent new NMSCs, in comparison with a control area receiving placebo-PDT, in patients with clinical and histological signs of field cancerization.
  • Methods Forty-five patients, previously diagnosed as having NMSCs of the face or scalp, with actinic keratoses symmetrically distributed over the same regions, were randomized for field treatment with 20% aminolaevulinic acid (ALA)-PDT on one side and placebo-PDT on the other.
  • Results A significant delay in the mean time of appearance and a reduction in the total number of new lesions were observed in the field-PDT protocol, when compared with the control.
  • Conclusions The results obtained showed that field therapy with ALA-PDT confers a significant preventive potential against the formation of new NMSCs in patients with field changes.
  • [MeSH-major] Facial Neoplasms / prevention & control. Head and Neck Neoplasms / drug therapy. Neoplasms, Second Primary / prevention & control. Photochemotherapy. Scalp. Skin Neoplasms / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Keratosis, Actinic / drug therapy. Male. Middle Aged. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863513.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Lim C, Martin P, Benger R, Kourt G, Ghabrial R: Lacrimal canalicular bypass surgery with the Lester Jones tube. Am J Ophthalmol; 2004 Jan;137(1):101-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The causes of lacrimal obstruction were idiopathic and trauma, congenital agenesis, infection, inflammation, herpes, basal cell carcinoma, radiation therapy, penicillin-induced Steven-Johnsons syndrome, systemic chemotherapy, and facial nerve palsy.
  • Complications were frequent and included extrusion, recurrent extrusion, malposition, obstruction, discomfort, infection, and diplopia.
  • CONCLUSIONS: Conjunctivodacryocystorhinostomy with the insertion of a Jones tube can be expected to improve epiphora significantly in most cases and remains the standard treatment for canalicular obstruction.
  • Complications occur in most cases, requiring replacement, repositioning, and cleaning of the tube by the ophthalmologist over an indefinite period of time.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Intraoperative Complications. Male. Middle Aged. Patient Satisfaction. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14700651.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ulrich C, Johannsen A, Röwert-Huber J, Ulrich M, Sterry W, Stockfleth E: Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol; 2010 Jul-Aug;20(4):482-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasing incidence rates of cutaneous malignancies, paralleling rising survival times of grafts and patients in organ transplant recipients, represents an escalating challenge for dermatologists worldwide.
  • Especially, invasive squamous cell carcinomas (SCC) in immuno-compromised patients are characterized by significantly increased morbidity and mortality and characteristically outnumber basal cell carcinoma in this population.
  • Diclofenac in hyaluronic acid has previously shown to be an effective and well tolerated option for the treatment of AK in immuno-competent patients.
  • 32 organ transplant patients (kidney (+/- pancreas), liver, heart) screened at our specialized transplant dermatology outpatient clinic were found eligible and were randomized to either active treatment (24) or vehicle (8).
  • Treatment of AK with 3% diclofenac in 2.5% hyaluronic acid or placebo twice daily was conducted over a total of 16 weeks, followed by a final evaluation 4 weeks after last application of the study drug.
  • Patients were assessed for safety variables that included adverse events, local skin reactions, laboratory results, dosage of immunosuppressive medication and indication of graft rejection.
  • A 24 months follow up was conducted after the end of treatment.
  • 87% (n = 28/32) of the patients completed the 16 week treatment phase and presented for final evaluation 4 weeks after end of treatment.
  • In the diclofenac 3% gel treatment group, a complete clearance of AK lesions was achieved in 41% (9/22) compared to 0% (0/6) in the vehicle group.
  • In 55% of the previously cleared patients, new AK developed in the study area after an average of 9.3 months.
  • None of these patients developed invasive SCC in the study area within 24 months of follow-up.
  • Despite recurrent AK in 55% of the previously cleared patients, the 24 month results showed no invasive SCC in this group.
  • This study suggests that diclofenac 3% gel is not only an efficient and well tolerated treatment for multiple AKs in OTRs but also may prevent invasive SCC in these high-risk patients.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diclofenac / therapeutic use. Keratosis, Actinic / drug therapy. Organ Transplantation
  • [MeSH-minor] Administration, Topical. Aged. Double-Blind Method. Female. Gels. Humans. Hyaluronic Acid / administration & dosage. Hyaluronic Acid / therapeutic use. Male. Middle Aged. Pilot Projects. Placebos. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507841.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 0 / Placebos; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


25. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB, Phase IV ALA-PDT Actinic Keratosis Study Group: Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol; 2006 Dec;155(6):1262-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.
  • AKs are believed to progress to in situ squamous cell carcinoma (SCC) and potentially, to invasive SCC.
  • Given these facts, the treatment and management of AKs are integral components to quality dermatological health care.
  • OBJECTIVES: Topical aminolaevulinic acid-based photodynamic therapy (ALA-PDT) has been extensively studied over the last several years.
  • (iii) to characterize the histopathology of untreated clinically diagnosed AK lesions in the study population at baseline; and (iv) to evaluate ALA-PDT in darker skin types than previously studied.
  • Individual AK lesions designated for treatment were graded as either grade 1 (lesions slightly palpable and more easily felt than seen) or grade 2 (moderately thick AKs, easily seen and felt).
  • The target AK lesions in the per-protocol population clearing completely in the first and second months following a single ALA-PDT treatment (baseline) were 76% and 72%, respectively.
  • Sixty per cent of the patients received a second ALA-PDT treatment, limited to the target AKs still present at month 2.
  • The percentage of treated target lesions that cleared completely peaked at 86% at month 4 then decreased gradually over time to 78% at month 12.
  • Of the 162 recurrent lesions 16 were lost to follow up, seven spontaneously cleared and 139 were biopsied.
  • With respect to the lesions biopsied, 91% (127/139) were diagnosed histopathologically as AK, with the balance of lesions being SCC (nine of 139: 7%), basal cell carcinoma (one of 139: 0.7%) and other non-AK diagnoses (two of 139: 1%).
  • The clinical diagnosis of AK by investigators appeared to be accurate, with 91% (200/220) of the untreated clinically diagnosed AK lesions being histopathologically confirmed to be AK (AK, 142/220: 65%; advanced AK, 29/220: 13%; macular AK, 29/220: 13%).
  • Despite concentrated efforts to recruit patients with Fitzpatrick skin types IV-VI, the distribution was as follows: I, 11%; II, 36%; III, 41%; IV, 11%; V, 2%.
  • CONCLUSIONS: ALA-PDT was shown to be an effective and safe therapy for the treatment of AKs of the face and scalp in skin types I-V, with an acceptable rate of recurrence over 12 months of histologically confirmed AKs of 19%.
  • Phototoxicity reactions were all expected, nonserious and had essentially resolved after 1 month post-treatment independent of skin type.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Facial Dermatoses / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107399.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


26. Sotiriou E, Apalla Z, Ioannides D: Fractionated 5-aminolevulinic acid photodynamic therapy in the treatment of a giant recurrent superficial basal cell carcinoma. Photodermatol Photoimmunol Photomed; 2009 Dec;25(6):331-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated 5-aminolevulinic acid photodynamic therapy in the treatment of a giant recurrent superficial basal cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906170.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down






Advertisement